tiprankstipranks
Trending News
More News >
Penumbra (PEN)
NYSE:PEN
US Market
Advertisement

Penumbra (PEN) Earnings Dates, Call Summary & Reports

Compare
461 Followers

Earnings Data

Report Date
Feb 24, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
1.09
Last Year’s EPS
0.97
Same Quarter Last Year
Based on 13 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 05, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance with significant revenue growth, particularly in the VTE and embolization segments, and positive developments in clinical trials, offset by some challenges in international markets and increased operational costs.
Company Guidance
During Penumbra's third-quarter 2025 conference call, the company reported total revenue of $354.7 million, marking a 17.8% year-over-year growth on a reported basis and 16.9% in constant currency. U.S. revenue reached $275 million, a 21.5% increase compared to the previous year. Specifically, U.S. thrombectomy sales rose by 18.5% to $192 million, while the VTE franchise led corporate growth with a 34% rise. Meanwhile, U.S. embolization and access revenue soared by 29.2% to $83 million. International revenue was $79.7 million, reflecting a 6.6% year-over-year increase. The company's gross margin expanded by 130 basis points to 67.8%, and operating income stood at $48.8 million, or 13.8% of revenue. Penumbra's guidance for the year was raised to $1.375 billion to $1.380 billion in revenue, with anticipated U.S. thrombectomy growth of 20% to 21% for 2025. The company remains focused on expanding its market presence, particularly through innovative products like the Lightning Bolt 16 and Lightning Flash 3.0, which have received FDA clearance.
Strong Revenue Growth
Total revenue reached $354.7 million, showing a year-over-year growth of 17.8% on a reported basis and 16.9% in constant currency. U.S. revenue grew by 21.5% to $275 million.
VTE Franchise Leading Growth
The VTE franchise delivered a 34% year-over-year growth, driving overall corporate growth.
Embolization and Access Revenue Surge
U.S. embolization and access revenue increased by 29.2% year-over-year to $83 million.
Gross Margin Expansion
Gross margin improved to 67.8%, up 130 basis points from the previous year, with expectations to reach over 70% by the end of 2026.
Positive Feedback for STORM-PE Trial
STORM-PE trial results showed CAVT superior in reducing right heart strain in PE patients with a favorable safety profile, receiving positive feedback from the medical community.
Raising Revenue Guidance
The company raised its revenue guidance for the year to $1.375 billion to $1.380 billion.

Penumbra (PEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

PEN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 24, 2026
2025 (Q4)
1.09 / -
0.97
Nov 05, 2025
2025 (Q3)
0.93 / 0.97
0.8514.12% (+0.12)
Jul 29, 2025
2025 (Q2)
0.82 / 0.86
0.6434.37% (+0.22)
Apr 23, 2025
2025 (Q1)
0.67 / 0.83
0.41102.44% (+0.42)
Feb 18, 2025
2024 (Q4)
0.90 / 0.97
0.7627.63% (+0.21)
Oct 30, 2024
2024 (Q3)
0.69 / 0.85
0.6726.87% (+0.18)
Jul 30, 2024
2024 (Q2)
0.56 / 0.64
0.4348.84% (+0.21)
May 07, 2024
2024 (Q1)
0.39 / 0.41
0.2378.26% (+0.18)
Feb 22, 2024
2023 (Q4)
0.70 / 0.76
0.16375.00% (+0.60)
Nov 02, 2023
2023 (Q3)
0.45 / 0.67
0.016600.00% (+0.66)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

PEN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 05, 2025
$225.54$264.61+17.32%
Jul 29, 2025
$227.15$254.21+11.91%
Apr 23, 2025
$278.77$298.25+6.99%
Feb 18, 2025
$271.14$303.76+12.03%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Penumbra (PEN) report earnings?
Penumbra (PEN) is schdueled to report earning on Feb 24, 2026, After Close (Confirmed).
    What is Penumbra (PEN) earnings time?
    Penumbra (PEN) earnings time is at Feb 24, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PEN EPS forecast?
          PEN EPS forecast for the fiscal quarter 2025 (Q4) is 1.09.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis